National Institutes of Health

**Name of Program**
Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R01 Clinical Trial Not Required)

**Deadline**
1/8/2019

**Brief Description**
The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices is not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery.

This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, orofacial pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.

LOI due 10/27/18; application due 11/27/18.

**National Institutes of Health**

**Discovery and Validation of Novel Targets for Safe and Effective Pain Treatment (R21 Clinical Trial Not Allowed)***

**Deadline:** 1/10/2019

**Brief Description:** This program announcement is intended to encourage new exploratory and developmental research projects to discover and validate novel targets for pain treatment. For example, such projects could assess the feasibility of a means to identify and validate a novel pain target. Another example could include the unique and innovative use of an existing methodology to explore an area of basic biology that could lead to the discovery of a novel pain treatment target. In any scenario, initial experiments to validate a target for pain treatment should be included in the application. These studies may involve considerable risk but may lead to a breakthrough in pain treatment. The focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices are not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, orofacial pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.

**LOI due 10/27/18; application due 11/27/18.**


**PCORI**

**Broad PCORI Funding Announcements -- Cycle 1 2019 (for Addressing Disparities, Assessment of Options, Communication and Dissemination Research, and Improving Healthcare Systems)**

**Deadline:** 1/31/2019

**Brief Description:** The Broad PCORI Funding Announcements (PFAs) seek investigator-initiated applications for patient-centered comparative clinical effectiveness research (CER) projects aligned with our priority areas for research. This PFA covers the following four priority areas: Addressing Disparities; Assessment of Prevention, Diagnosis, and Treatment Options; Communication and Dissemination Research, and Improving Healthcare Systems. Applications should address needs of patients, caregivers, clinicians, and other healthcare stakeholders in making personalized clinical decisions across a wide range of conditions, populations, and treatments. Note: In general, PCORI will not cover costs for interventions that are being compared in the proposed study. Our National Priorities for Research and Research Agenda is a framework to guide our funding of comparative clinical effectiveness research that will give patients and those who care for them the ability to make better-informed health decisions.

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Name of Program</th>
<th>Deadline</th>
<th>Brief Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>National Institutes of Health</td>
<td>Health Services Research on Minority Health and Health Disparities (R21 Clinical Trial Optional)</td>
<td>4/11/2019</td>
<td>The purpose of this Funding Opportunity Announcement (FOA) is to encourage innovative exploratory and developmental health services research to improve minority health and/or reduce health disparities at the health care system-level as well as within clinical settings.</td>
</tr>
</tbody>
</table>

**Mechanism**  
R21


**Total Number of Opportunities**  
4